Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS.
Vonk SEM, van der Meer-Vos M, Kos R, Neerincx AH, Terheggen-Lagro SWJ, Altenburg J, Maitland-van der Zee AH, Mathôt RAA, Kemper EM; Amsterdam Mucociliary Clearance Disease (AMCD) research group. Vonk SEM, et al. Ther Drug Monit. 2024 Aug 27;46(6):804-12. doi: 10.1097/FTD.0000000000001231. Online ahead of print. Ther Drug Monit. 2024. PMID: 38935410 Free PMC article.
Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
Vonk SEM, Lub R, Weersink EJM, Beuers U, Mathôt RAA, Kemper EM, Altenburg J; Amsterdam Mucociliary Clearance Disease Research Group. Vonk SEM, et al. Clin Ther. 2024 Feb;46(2):154-158. doi: 10.1016/j.clinthera.2023.11.003. Epub 2023 Dec 1. Clin Ther. 2024. PMID: 38042631 Free article.
Real-life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients.
Kos R, Neerincx AH, Fenn DW, Brinkman P, Lub R, Vonk SEM, Roukema J, Reijers MH, Terheggen-Lagro SWJ, Altenburg J, Majoor CJ, Bos LD, Haarman EG, Maitland-van der Zee AH; Amsterdam Mucociliary Clearance Disease (AMCD) Research Group. Kos R, et al. Among authors: vonk sem. Pharmacol Res Perspect. 2022 Dec;10(6):e01015. doi: 10.1002/prp2.1015. Pharmacol Res Perspect. 2022. PMID: 36440690 Free PMC article.
Tobramycin and vestibulotoxicity: retrospective analysis of four cases.
Vonk SEM, Weersink EJM, Majoor CJ, Kemper EM; Amsterdam Mucociliary Clearance Disease (AMCD) Research Group. Vonk SEM, et al. Eur J Hosp Pharm. 2022 Mar;29(e1):e88-e90. doi: 10.1136/ejhpharm-2020-002588. Epub 2021 Mar 22. Eur J Hosp Pharm. 2022. PMID: 33753422 Free PMC article.
Quantitative Method for the Analysis of Ivacaftor, Hydroxymethyl Ivacaftor, Ivacaftor Carboxylate, Lumacaftor, and Tezacaftor in Plasma and Sputum Using Liquid Chromatography With Tandem Mass Spectrometry and Its Clinical Applicability.
Vonk SEM, van der Meer-Vos M, Bos LDJ, Neerincx AH, Majoor CJ, Maitland-van der Zee AH, Mathôt RAA, Kemper EM; Amsterdam Mucociliary Clearance Disease (AMCD) research group. Vonk SEM, et al. Ther Drug Monit. 2021 Aug 1;43(4):555-563. doi: 10.1097/FTD.0000000000000829. Ther Drug Monit. 2021. PMID: 33165217 Free PMC article.